MSC Paracrine Signaling in Inflammatory Arthritis
Analysis of preclinical studies: MSC‑derived exosomes reduce synovial inflammation and joint damage.
Read
AUTOIMMUNE RESEARCH REVIEW
Mesenchymal Stem Cell Immunomodulation in Autoimmune Diseases: Mechanisms and Early Evidence
This article synthesizes findings from preclinical models and early‑phase clinical studies examining the use of MSCs as an immunomodulatory adjunct in autoimmune conditions. Emphasis is placed on paracrine mechanisms (IL‑10, TGF‑β, exosomes), Treg expansion, and reported safety profiles in rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease.
Access review
Rheumatoid Arthritis
Systemic Lupus
Immunomodulatory Effects of MSCs in Lupus Nephritis
Case series and early trials report Treg restoration and reduced autoantibody titers; controlled studies ongoing.
Review
Multiple Sclerosis
MSC Paracrine Mechanisms in Neuroinflammation
Current evidence from phase I/II trials demonstrates that MSCs modulate microglial activation and promote neuroprotection; symptomatic benefit under investigation.
Explore
IBD / Crohn's
MSC Therapy for Fistulizing Crohn's Disease: Adjunctive Use
Systematic review highlights limited low‑bias evidence; local MSC administration shows safety and can achieve fistula closure in refractory cases.
Synopsis
Sjögren's Syndrome
MSC Immunomodulation in Autoimmune Epithelitis
Preclinical models show reduced lymphocytic infiltration and improved glandular function; human trials warranted.
Abstract
Type 1 Diabetes
Preserving Beta‑Cell Function with MSC Paracrine Signals
Early clinical evidence: immunomodulation can slow C‑peptide decline; large RCTs needed.
ReadMSC in Rheumatoid Arthritis
Paracrine signaling reduces synovitis.
Lupus Nephritis
Treg restoration and safety data.
MSC in Multiple Sclerosis
Neuroinflammation modulation.
Crohn's Fistulas
Adjunctive MSC safety review.